India to Algeria Pharmaceutical Export

The pharmaceutical trade between India and Algeria has experienced significant growth over the past decade. In 2017, India's pharmaceutical exports to Algeria were valued at approximately $79.23 million. By 2024, this figure had increased to $77.38 million, indicating a steady upward trajectory in bilateral trade.

A pivotal milestone in this relationship occurred in January 2026, when the India-Algeria Pharmaceutical Business Forum was held in Algiers. This forum saw the participation of nearly 100 Indian pharmaceutical companies, underscoring the growing interest and commitment to strengthening ties in the sector. The event facilitated discussions on joint investment projects and technology transfer, aiming to position Algeria as a regional hub for pharmaceutical production and export. (news.radioalgerie.dz)

The forum's success was further highlighted by the presence of over 65 Indian pharmaceutical companies, reflecting the strategic importance both nations place on this partnership. The discussions centered on leveraging Algeria's strategic geographical position and infrastructure to access broader African and Mediterranean markets. (news.radioalgerie.dz)

India's pharmaceutical exports to Algeria have consistently been a significant component of the country's total exports to Algeria. In 2024, pharmaceutical products accounted for approximately $77.38 million of the total $943.71 million in exports to Algeria. This underscores the strategic importance of the pharmaceutical sector in India's trade relations with Algeria.

The partnership is mutually beneficial, with India recognized as the "pharmacy of the world" and Algeria positioning itself as a growing pharmaceutical hub in Africa. The collaboration aims to enhance local production capabilities in Algeria, reduce dependency on imports, and expand market access for Indian pharmaceutical companies in the African continent. (news.radioalgerie.dz)

Between 2024 and 2026, several key developments have further solidified the India-Algeria pharmaceutical trade corridor. In January 2026, the India-Algeria Pharmaceutical Business Forum was held in Algiers, with nearly 100 Indian pharmaceutical companies participating. The forum focused on joint investment projects and technology transfer, aiming to establish Algeria as a regional hub for pharmaceutical production and export. (news.radioalgerie.dz)

In February 2026, a multi-product Indian business delegation, led by the Federation of Indian Export Organisations (FIEO), visited Algeria to strengthen bilateral trade ties and foster long-term business partnerships. The delegation included representatives from the pharmaceutical sector, highlighting the ongoing commitment to enhancing cooperation in this field.

These initiatives reflect a concerted effort by both nations to deepen their pharmaceutical trade relations, focusing on joint ventures, technology transfer, and expanding market access in regional and African markets.

To market pharmaceutical products in Algeria, Indian companies must obtain registration from the National Agency for Pharmaceutical Products (ANPP). The registration process involves submitting a comprehensive dossier that includes product information, clinical data, and certificates such as the Certificate of Pharmaceutical Product (CPP) and Good Manufacturing Practice (GMP) certificates. The dossier should be presented in the Common Technical Document (CTD) format, which is internationally recognized and facilitates the evaluation process. The ANPP evaluates the dossier to ensure the product's safety, efficacy, and quality before granting marketing authorization.

In December 2025, the ANPP streamlined the drug registration process to enhance efficiency. Under the new system, pharmaceutical product registration files are presented to the Drug Registration Committee only once. If the committee raises objections, the registration file is suspended until the pharmaceutical company addresses and resolves all concerns. Once the concerns are resolved, the registration decision is issued without requiring the file to be re-submitted to the Registration Committee. (dzwatch.dz)

Algeria requires pharmaceutical manufacturing facilities to comply with Good Manufacturing Practice (GMP) standards recognized by the ANPP. The ANPP conducts inspections to ensure that manufacturing sites adhere to these standards, which are essential for ensuring the quality and safety of pharmaceutical products. In September 2025, the Ministry of Pharmaceutical Industry updated the authorization framework for pharmaceutical manufacturing establishments, introducing new documentation and procedural requirements. The authorization process now includes a two-stage approval: preliminary approval for project initiation and activity launching approval for operational commencement. Noncompliance with the new regulations may lead to application rejections, affecting project timelines and operational readiness.

To import pharmaceutical products into Algeria, companies must obtain an import authorization from the Ministry of Pharmaceutical Industry. The application for authorization must be accompanied by a file containing various documents, including the Certificate of Pharmaceutical Product (CPP), Certificate of Analysis (CoA), and GMP certificates. These documents ensure that the imported products meet the required quality standards. The ANPP evaluates the documentation to ensure compliance with Algerian regulations before granting import authorization. (miph.gov.dz)

India's pharmaceutical exports to Algeria are predominantly concentrated in therapeutic areas addressing infectious diseases, respiratory conditions, and cardiovascular events. The leading product, Rifampicin Capsules BP 150 mg, accounting for $7.9 million (10.4% of total exports), is a cornerstone in the treatment of tuberculosis, a disease with a significant prevalence in Algeria. The prominence of respiratory medications, exemplified by the Budecort 200 Inhaler (Budesonide 200mcg), reflects the high incidence of asthma and chronic obstructive pulmonary disease (COPD) in the region. Additionally, cardiovascular treatments like recombinant tissue plasminogen activator (TNK-TPA) injections are critical in managing acute myocardial infarctions, aligning with Algeria's efforts to enhance acute care services.

These therapeutic categories dominate due to Algeria's substantial burden of infectious diseases, respiratory disorders, and cardiovascular events. The Algerian government's focus on improving healthcare infrastructure and access to essential medicines has led to increased demand for these treatments. The National Drug Regulatory Authority's adherence to WHO-GMP standards ensures the quality and efficacy of imported pharmaceuticals, further driving the demand for these specific therapeutic areas.

Algeria's pharmaceutical market is witnessing a surge in demand for generic drugs, driven by government initiatives to reduce healthcare costs and promote domestic production. The establishment of the Ministry of Pharmaceutical Industry (MOPI) and the National Agency for Pharmaceutical Products (ANPP) has streamlined drug registration processes, significantly reducing approval times for generic medicines. This regulatory facilitation presents Indian pharmaceutical companies with opportunities to introduce cost-effective generics, particularly in areas where patent protections are expiring, known as patent cliffs. Additionally, Algeria's growing focus on biosimilars offers Indian exporters a chance to supply high-quality, affordable alternatives to expensive biologic therapies, catering to the needs of patients requiring such treatments.

Algeria's disease burden, characterized by a high prevalence of chronic conditions such as diabetes, cardiovascular diseases, and respiratory disorders, significantly drives the demand for pharmaceutical imports. The economic burden of managing these diseases is substantial; for instance, the annual median cost of treating diabetic foot ulcers is estimated at €3,790.97 per patient, highlighting the financial strain on the healthcare system. Despite efforts to increase domestic production, Algeria continues to rely heavily on imported pharmaceuticals, with imports accounting for 70% of the market share. This dependency underscores the critical role of international suppliers, like India, in meeting the country's healthcare needs. Furthermore, Algeria's healthcare spending per capita has been on a declining trend, from $242.07 in 2019 to $179.70 in 2022, indicating budgetary constraints that may limit the affordability of imported medicines. This scenario presents both challenges and opportunities for Indian pharmaceutical exporters to offer cost-effective solutions that align with Algeria's economic realities.

Algeria's tariff structure for pharmaceutical formulations, particularly those classified under HS codes 3003 and 3004, is influenced by its trade policies and international agreements. While specific Most-Favored-Nation (MFN) tariff rates for these products are not readily available, Algeria's MFN tariff rates for pharmaceutical products typically range from 0% to 5%, depending on the specific product and its classification. This range aligns with Algeria's commitment to facilitating access to essential medicines.

Regarding preferential duty rates, Algeria is a member of the Arab Maghreb Union (UMA), which aims to promote economic integration among member states. However, the UMA has been largely inactive in recent years, and there are no significant preferential duty rates currently in place for pharmaceutical products between India and Algeria. Additionally, Algeria has been known to implement temporary anti-dumping measures on certain pharmaceutical imports to protect domestic industries. These measures can include additional duties or restrictions on specific products deemed to be sold at unfairly low prices. It is advisable for Indian pharmaceutical exporters to monitor Algeria's trade policies regularly to stay informed about any such measures.

As of March 2026, there is no active Free Trade Agreement (FTA) between India and Algeria. The absence of such an agreement means that pharmaceutical products exported from India to Algeria are subject to standard MFN tariff rates without any preferential treatment. While there have been discussions about enhancing bilateral trade relations, no concrete steps have been taken to establish an FTA. The lack of an FTA can impact the competitiveness of Indian pharmaceutical products in the Algerian market, as they do not benefit from reduced tariffs that could be available under preferential trade agreements.

Algeria's intellectual property (IP) framework, particularly concerning patents, is designed to protect both domestic and foreign innovations. The country adheres to international IP agreements, including the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. This adherence means that patents granted in Algeria are generally recognized and enforced, providing protection for pharmaceutical inventions. However, Algeria has provisions for compulsory licensing, allowing the government to grant licenses to third parties without the consent of the patent holder under specific circumstances, such as public health emergencies. This mechanism can affect the entry of generic drugs into the market, as it may facilitate the production of generic versions of patented medicines. Indian pharmaceutical companies should be aware of these provisions when considering market entry strategies in Algeria, as they may influence the competitive landscape for generic drugs.

Algeria's pharmaceutical market is projected to reach a revenue of US$1.06 billion by 2025, with an anticipated compound annual growth rate (CAGR) of 4.03% from 2025 to 2030, resulting in a market volume of US$1.29 billion by 2030. The market is characterized by a significant presence of generic drugs, driven by government initiatives to reduce healthcare costs and promote domestic production.

Algeria provides universal healthcare coverage to its citizens through two main public health insurance schemes: the Caisse Nationale de la Sécurité Sociale des Travailleurs Salariés (CNAS) for salaried employees and their dependents, and the Caisse Nationale des Assurances Sociales des Non-Salariés (CASNOS) for non-salaried professionals. These programs offer free access to medical care and medications at state-run hospitals and clinics. In January 2026, the government introduced an electronic card granting free access to medicines for citizens without social coverage, further expanding healthcare access. (dzair-tube.dz)

The Algerian pharmaceutical market presents significant opportunities for Indian exporters, particularly in the generic drug segment. With a projected market volume of US$1.29 billion by 2030, the demand for cost-effective medications is expected to rise, aligning with India's strengths in generic drug manufacturing. The government's focus on reducing healthcare costs and promoting domestic production creates a favorable environment for Indian pharmaceutical companies to expand their presence in Algeria.